Losmapimod Demonstrates Significant Slowing of FSHD

Durability of treatment response on reachable workspace was observed among those who continued losmapimod throughout the 96-week period and those who switched from placebo.

New long-term findings from the phase 2b ReDUX4 trial (NCT04003974) showed that treatment with losmapimod (Fulcrum Therapeutics) slowed disease progression and demonstrated maintenance of effect through a 96-week period in patients with facioscapulohumeral muscular dystrophy (FSHD), expanding on the previously reported 48-week results.1